Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


MSAC mulls blood market

Posted 19 November 2020

The second part of a review of the $924 million immunoglobulin market will be considered by MSAC next week when a $206,800 report developed by Monash University goes before the committee.

MSAC is conducting a clinical and cost effectiveness review of the National Blood Authority (NBA) immunoglobulin (Ig) market, worth $924 million for the five years to 2020, with the bulk of the market supplied by CSL Behring. CSL's contract - worth $569 million over the five year period - concludes at the end of this year.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Picking the path out of Covid
Now is not the time for leaders to play it safe
Special Report
Aust Covid Vaccine Tracker
UPDATE: Gilead hits back at WHO over remdesivir
Approvals Action
Trio of new drugs on ARTG
Roche, Seqirus, Clinuvel enlarge local portfolios